AIR-CF1: Adverse Reactions
CAYSTON's safety profile was clinically evaluated in multiple studies
The safety profile of CAYSTON was evaluated in 344 patients from 2 placebo-controlled trials (AIR-CF1 and AIR-CF2) and 1 open-label follow-on trial (AIR-CF3).
In the 2 controlled trials, 146 patients with CF received 75 mg CAYSTON 3 times a day for 28 days.
Adverse reactions reported in ≥5% of patients treated with CAYSTON in the placebo-controlled trials
Adverse reactions that occurred in <5% of patients treated with CAYSTON were bronchospasm (3%) and rash (2%).
Low incidence of altered taste: In AIR-CF1, dysgeusia (altered taste) was reported by 1 patient treated with 75 mg CAYSTON and 1 placebo-treated patient.4